<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02156089</url>
  </required_header>
  <id_info>
    <org_study_id>140120</org_study_id>
    <secondary_id>14-AA-0120</secondary_id>
    <nct_id>NCT02156089</nct_id>
  </id_info>
  <brief_title>Neuroimaging, Omega-3 and Reward in Adults With ADHD (NORAA) Trial</brief_title>
  <official_title>Neuroimaging Omega-3 and Reward in Adults With ADHD (NORAA) Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      Background:&#xD;
&#xD;
      - People with attention-deficit hyperactivity disorder (ADHD) often have problems with&#xD;
      motivation and rewards. . Omega-3 fats have helped symptoms of ADHD improve in children.&#xD;
      Researchers want to learn more about the brain activity of people with ADHD and see how&#xD;
      taking omega-3 fats might help.&#xD;
&#xD;
      Objective:&#xD;
&#xD;
      - To learn more about how omega-3 fats affect brain activity and ADHD symptoms.&#xD;
&#xD;
      Eligibility:&#xD;
&#xD;
      - Adults age 18 55 with ADHD symptoms.&#xD;
&#xD;
      Design:&#xD;
&#xD;
        -  Participants will be screened with medical history and review of medical records.&#xD;
&#xD;
        -  For study visit 1, participants will have a medical examination and be interviewed to&#xD;
           confirm they have ADHD. They will have an IQ test and give blood and urine samples.&#xD;
           Height, weight, and blood pressure will be measured. They will also need to sign consent&#xD;
           to agree to take part in the study. They will be asked to complete a food diary for 4&#xD;
           days&#xD;
&#xD;
        -  For visit 2, participants will give a blood sample. They will complete questionnaires&#xD;
           about their mood and ADHD symptoms.. They may give a blood or saliva sample for genetic&#xD;
           testing.&#xD;
&#xD;
        -  Participants will have a magnetic resonance imaging (MRI) scan. They will lie on a table&#xD;
           that slides in and out of a metal cylinder. It makes loud noises; participants will get&#xD;
           earplugs. This scan examines the structure of the brain.&#xD;
&#xD;
        -  Participants will have a functional MRI scan. This scan measures the function of the&#xD;
           brain while the volunteer is performing tasks in the scanner. They will stop ADHD&#xD;
           medications 48 hours before this scan.&#xD;
&#xD;
        -  Participants will receive key-lime flavored omega-3 smoothie mix or placebo to takeevery&#xD;
           day&#xD;
&#xD;
        -  For visit 3, participants will give blood samples and complete questionnaires.&#xD;
&#xD;
        -  For visit 4, participants will be weighed and have a blood test and MRI scans as per&#xD;
           before. They will repeat the questionnaires and will guess whether they received the&#xD;
           omega-3 or placebo.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objective:&#xD;
&#xD;
      Both attention deficit hyperactivity disorder (ADHD) and addictive behaviors have been&#xD;
      persistently related to impaired reward-related processes in the ventral striatum as&#xD;
      evidenced by functional magnetic resonance imaging studies (fMRI). These impairments&#xD;
      characterized by decreased BOLD activation are thought to be linked to dopamine pathways&#xD;
      including decreased D2 receptor function. Omega-3 highly unsaturated fatty acids (HUFAs) are&#xD;
      critical for cell-signaling among other complex functions throughout the central nervous&#xD;
      system. Animal models have demonstrated that depriving animals of the omega-3 DHA in utero&#xD;
      significantly decreases the density of ventral striatal D2- like receptors and furthermore&#xD;
      depletes dopamine in the nucleus acumens by 40-60%. The behavioral profile of animals&#xD;
      subjected to dietary induced deficiencies of omega-3 reflect decreased goal-directed behavior&#xD;
      and increased goal-irrelevant activity, hyperactivity, increased anxiety and reduced behavior&#xD;
      flexibility. Abnormally low levels of omega-3 HUFAs have been persistently reported in the&#xD;
      erythrocytes of both children and adults with ADHD while supplementation with omega-3 HUFAs&#xD;
      was found in a meta-analysis of 10 clinical trials to improve symptoms of ADHD. However, to&#xD;
      date no one has tested the potential mediating effects of omega-3 supplementation in&#xD;
      reward-related processes in adults with ADHD using neuroimaging techniques. There is hence a&#xD;
      need to research the potential treatment effects of omega-3 on assessments of brain function.&#xD;
      Therefore, the primary objective of this study is to test the effects of omega-3 intervention&#xD;
      (compared to a placebo) in increasing ventral striatal activation during the monetary&#xD;
      incentive delay (MID) task. Secondary objectives include collecting neuroimaging data and&#xD;
      standardized questionnaires measuring, mood, quality of life and symptoms of ADHD.&#xD;
&#xD;
      Study Population:&#xD;
&#xD;
      150 adults, other-wise healthy, aged 18-55 with ADHD.&#xD;
&#xD;
      Design:&#xD;
&#xD;
      The active group will be stratified according to age and sex to either an active intervention&#xD;
      group receiving (1) 3000 mg of omega-3 HUFA smoothie or a placebo group (2) 3000 mg of&#xD;
      smoothie macadamia nut oil for 16 weeks. After enrollment and baseline testing, active&#xD;
      participants will be randomized to either the treatment or placebo group and instructed to&#xD;
      begin consumption of assigned emulsions. Randomized participants will be assessed at&#xD;
      baseline, 1 month, 8 weeks, and 16 weeks.&#xD;
&#xD;
      Outcome Measures:&#xD;
&#xD;
      The primary outcome assessments will measure ventral-striatum activation during the MID task.&#xD;
      Secondary objectives include: structural MRI, symptoms of ADHD using the Conner s Adult ADHD&#xD;
      Rating Scales; negative affective symptoms; endocannabinoid levels and weight change.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>June 4, 2014</start_date>
  <completion_date type="Actual">December 21, 2018</completion_date>
  <primary_completion_date type="Actual">December 21, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>To test if omega-3 HUFA intervention results in greater ventral-striatal activation during a reward task in adults with ADHD compared to a placebo group between baseline and follow up at 16 weeks.</measure>
    <time_frame>baseline and afte 15 weeks</time_frame>
  </primary_outcome>
  <enrollment type="Actual">63</enrollment>
  <condition>Attention Deficit Disorder</condition>
  <condition>Attention Deficit Hyerpactivity Disorder</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Highly unsaturated omega-3 fatty acids</intervention_name>
    <description>Nitrient - Matched Placebo of 3 g/d of macademia nut oil (in comparison to 3 g/d of omega-3 highly unsaturated fatty acids).</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:&#xD;
&#xD;
        Participants will be 18 or over and up to 55 years old.&#xD;
&#xD;
          -  In general good health.&#xD;
&#xD;
          -  Body Mass Index (BMI) between 18 and 35.&#xD;
&#xD;
          -  Able to come to the NIH clinical center for each of their scheduled appointments for&#xD;
             the duration of the study and have a working phone number.&#xD;
&#xD;
          -  Able to understand the consent form and provide written informed consent.&#xD;
&#xD;
          -  Have an IQ of 70 or greater as assessed by the WASI for fast IQ testing (a score of&#xD;
             less than this is considered to have global intellectual disability - classified in&#xD;
             DSM-IV as mental retardation). There are often issues around the ability to give&#xD;
             informed consent in adults with global intellectual disability.&#xD;
&#xD;
          -  Meet DSM diagnostic criteria for ADHD as assessed by the CAADID Conners Adult ADHD&#xD;
             Diagnostic Interview for DSM-IV.&#xD;
&#xD;
          -  Have significant symptoms of ADHD despite concurrent pharmacological and psychological&#xD;
             therapies as assessed by the Connors Adult ADHD rating scale (CAARS) (as assessed at&#xD;
             telephone screen).&#xD;
&#xD;
          -  Be willing to have a 48hour wash-out of stimulant medication prior to both baseline&#xD;
             and follow-up scans.&#xD;
&#xD;
          -  Willing to stop all nutritional supplements including omega-3 fats.&#xD;
&#xD;
          -  Willing to stop eating seafood for the study duration of 16 weeks.&#xD;
&#xD;
          -  Be willing to have 2 MRI scanning sessions.&#xD;
&#xD;
          -  People who are willing to take the smoothie emulsion every day for 16 weeks.&#xD;
&#xD;
        EXCLUSION CRITERIA:&#xD;
&#xD;
          -  Any medical illness or treatment that in the view of the investigators would&#xD;
             compromise participation in research or participant safety, as determined by medical&#xD;
             history, physical examination, laboratory tests (see details under Screening measures&#xD;
             below), including, but not limited to:&#xD;
&#xD;
          -  Unstable medical conditions requiring immediate intervention.&#xD;
&#xD;
          -  Unstable or rapidly progressive neurological diseases.&#xD;
&#xD;
          -  History hemorrhagic or ischemic stroke within the last 3 months.&#xD;
&#xD;
          -  Known heart disease.&#xD;
&#xD;
          -  Hypertension.&#xD;
&#xD;
          -  Asthma&#xD;
&#xD;
          -  If the participant is related to the study investigator or their superior,&#xD;
             subordinate, or immediate family member.&#xD;
&#xD;
          -  HIV positive.&#xD;
&#xD;
          -  Significant dietary limitations:&#xD;
&#xD;
        Allergy, hypersensitivity, or intolerance to fish oils or omega-3 fats which are found in&#xD;
        fish..&#xD;
&#xD;
          -  Allergy, hypersensitivity, or intolerance to Macadamia nuts or any nuts such as&#xD;
             almonds, walnuts, pecans, peanuts, etc.&#xD;
&#xD;
          -  Pregnancy or breastfeeding (by urine pregnancy test; self-report).&#xD;
&#xD;
          -  Reported consumption of fish and seafood three or more times per week within the last&#xD;
             three months.&#xD;
&#xD;
          -  Regular consumption of omega-3 supplements (e.g., cod liver oil, borage oil, fish oil&#xD;
             or evening primrose oil) , defined as an average of 250 mg/day of omega-3 HUFAs over&#xD;
             the previous 3 months.&#xD;
&#xD;
          -  Severe alcohol or substance use disorder according to the AUDIT.&#xD;
&#xD;
          -  Acute intoxication or withdrawal from alcohol or other CNS active substances to the&#xD;
             extent that they may impair capacity to provide informed consent or participate in&#xD;
             research.&#xD;
&#xD;
          -  Some neuropsychiatric disorders are either so rare or associated with such profound&#xD;
             alterations of brains structure and function that they will be excluded. This includes&#xD;
             a diagnosis of severe Bipolar disorders or Axis 1 psychotic disorder assessed by SCID,&#xD;
             including schizophrenia, psychosis NOS, autism, substance dependence; dementia, eating&#xD;
             disorder.&#xD;
&#xD;
          -  Cognitive impairment severe enough to preclude informed consent or valid responses on&#xD;
             self-report questionnaires.&#xD;
&#xD;
          -  Behavioral instability significant enough to impair ability for consent and&#xD;
             participation.&#xD;
&#xD;
          -  Participation in other research studies that in the opinion of the investigators would&#xD;
             interfere with study outcomes or study compliance.&#xD;
&#xD;
          -  On any of the following medications: Atomoxetine (Strattera), bupropion (Wellbutrin),&#xD;
             tricyclic antidepressants (imipramine), alpha adrenergic agonists (clonidine,&#xD;
             guanfacine) or modafinil (Provigil) depending whether dose interferes with scan and&#xD;
             whether or not patient can stay on same dose throughout study.&#xD;
&#xD;
          -  Use of non-steroidal anti-inflammatory drugs (NSAIDs), dalteparin, dipyrdamole,&#xD;
             enoxaparin, ticlopedine, more than once per week within the last three months.&#xD;
&#xD;
          -  Living situation unsuitable for the storage or use of intervention materials.&#xD;
&#xD;
        MRI Exclusion Criteria:&#xD;
&#xD;
          -  Have ferromagnetic objects in their bodies, which might be adversely affected by MRI&#xD;
             (e.g., surgical clips, metal fragments in or near brain, eye or blood vessels, cardiac&#xD;
             or neurological pacemaker, cochlear or eye implant). Any doubt about presence of these&#xD;
             objects will result in exclusion from this study.&#xD;
&#xD;
          -  Extreme claustrophobia.&#xD;
&#xD;
          -  Left-handed individuals.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph R Hibbeln, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Bondi CO, Taha AY, Tock JL, Totah NK, Cheon Y, Torres GE, Rapoport SI, Moghaddam B. Adolescent behavior and dopamine availability are uniquely sensitive to dietary omega-3 fatty acid deficiency. Biol Psychiatry. 2014 Jan 1;75(1):38-46. doi: 10.1016/j.biopsych.2013.06.007. Epub 2013 Jul 25.</citation>
    <PMID>23890734</PMID>
  </reference>
  <reference>
    <citation>Zimmer L, Delion-Vancassel S, Durand G, Guilloteau D, Bodard S, Besnard JC, Chalon S. Modification of dopamine neurotransmission in the nucleus accumbens of rats deficient in n-3 polyunsaturated fatty acids. J Lipid Res. 2000 Jan;41(1):32-40.</citation>
    <PMID>10627499</PMID>
  </reference>
  <reference>
    <citation>Zimmer L, Delpal S, Guilloteau D, AÃ¯oun J, Durand G, Chalon S. Chronic n-3 polyunsaturated fatty acid deficiency alters dopamine vesicle density in the rat frontal cortex. Neurosci Lett. 2000 Apr 21;284(1-2):25-8.</citation>
    <PMID>10771153</PMID>
  </reference>
  <verification_date>December 21, 2018</verification_date>
  <study_first_submitted>June 4, 2014</study_first_submitted>
  <study_first_submitted_qc>June 4, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 5, 2014</study_first_posted>
  <last_update_submitted>December 22, 2018</last_update_submitted>
  <last_update_submitted_qc>December 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>fMRI</keyword>
  <keyword>Reward Processing</keyword>
  <keyword>Nutrition</keyword>
  <keyword>Omega-3 Fatty Acids</keyword>
  <keyword>ADHD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

